# Recombinant Human Superoxide Dismutase (rhSOD) and Vascular Reactivity

> **NCT00264186** · PHASE1 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 43 (—)

## Conditions studied

- Inflammation

## Interventions

- **DRUG:** LPS 2 ng/kg intravenous (IV) bolus
- **DRUG:** rhSOD 82,000 IU (8.2 mg)/min intraarterially
- **DRUG:** Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)
- **DRUG:** Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)
- **DRUG:** Glyceroltrinitrate (nitroglycerine) 4, 8, 16 nmol/min over 3 min/dose level (two times; pre-dose and +3.5 hrs)

## Key facts

- **NCT ID:** NCT00264186
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 43 (—)
- **Last updated:** 2008-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00264186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00264186, "Recombinant Human Superoxide Dismutase (rhSOD) and Vascular Reactivity". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00264186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*